TL;DR
This paper presents a new, highly sensitive method using Selected Reaction Monitoring Mass Spectrometry (SRM-MS) to identify potential protein biomarkers in cerebrospinal fluid (CSF) for Secondary Progressive Multiple Sclerosis (SPMS). They identified five proteins that differ between SPMS patients, neurological disorder controls, and healthy individuals, and eleven proteins affected by lamotrigine treatment, paving the way for better SPMS diagnosis and treatment.
What Problem Does This Paper Address?
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system that can evolve into Secondary Progressive MS (SPMS). SPMS is characterized by a slow, continuous neurological decline, and currently, there's no definitive diagnostic marker for this stage. This diagnostic lag means patients might not receive appropriate care for years. Furthermore, understanding the underlying mechanisms of SPMS is crucial for developing effective treatments, but this is hampered by the lack of reliable biomarkers. The paper aims to address this by developing a robust method to identify and quantify proteins in CSF that could serve as these much-needed biomarkers.
Methods
The core of this research is the development and application of a multiplexed Selected Reaction Monitoring Mass Spectrometry (SRM-MS) assay. SRM-MS is a targeted mass spectrometry technique that offers high specificity and sensitivity for quantifying specific peptides (and thus proteins) in complex biological samples like CSF.
Here's a breakdown of their approach:
- Assay Development: They developed a highly specific and sensitive SRM assay capable of simultaneously detecting 26 potential protein biomarkers. This involved optimizing sample preparation, liquid chromatography (LC) separation, and mass spectrometry parameters.
- Internal Standard: Intact horse apomyoglobin was used as an internal standard for quantitative measurements, allowing for more accurate and reproducible protein level estimations.
- Limit of Detection (LOD): They established a very low LOD of one femtomole per microliter, indicating the assay's ability to detect even trace amounts of proteins.
- Sample Preparation: A detailed protocol for CSF sample preparation was outlined, including protein digestion with trypsin and desalting.
- LC-MS/MS: A high-performance liquid chromatography system was coupled to a triple quadrupole mass spectrometer for the separation and detection of peptides.
- Data Analysis: Statistical methods like Analysis of Variance (ANOVA) and Principal Component Analysis (PCA) were used to analyze the quantitative protein data and identify significant differences between patient groups and treatment conditions.
Datasets
The study utilized cerebrospinal fluid (CSF) samples from four distinct groups:
- SPMS patients:
- 12 from the National Institute of Neurological Disorders and Stroke (NINDS) at NIH.
- 10 from the placebo group of a lamotrigine trial.
- Non-inflammatory neurological disorder (NIND) controls: 12 individuals.
- Healthy Controls (HC): 10 individuals.
In total, 51 subjects contributed samples. The paper also mentions using pooled CSF samples from patients without identified medical records for initial method development.
Key Insights and Ideas
- CSF as a Biomarker Source: The study reinforces the value of CSF as a rich source of biomarkers for neurodegenerative diseases, as its composition directly reflects brain metabolic processes.
- SRM-MS for Targeted Proteomics: The research highlights the power of SRM-MS as a platform for developing and verifying protein biomarkers, offering a balance of sensitivity, specificity, and throughput.
- Complexity of SPMS Biomarkers: The findings suggest that a single protein biomarker is unlikely to be sufficient for diagnosing SPMS, and a panel of indicators will likely be necessary.
- Lamotrigine's Potential Impact: Even though the lamotrigine trial itself was negative for clinical outcomes, the proteomic analysis revealed that lamotrigine treatment significantly decreased the expression of eleven proteins, suggesting a potential mechanism of action or a link to disease pathways.
Key Results
- Differential Protein Expression:
- SPMS vs. HC: One protein showed a significant difference.
- SPMS vs. NIND: Three proteins showed significant differences.
- NIND vs. HC: Two proteins showed significant differences.
- Lamotrigine Treatment Effect: Eleven proteins were found to be expressed significantly lower in SPMS patients treated with lamotrigine compared to untreated SPMS patients.
- Assay Performance: The developed SRM assay demonstrated high specificity and sensitivity, with a limit of detection as low as one femtomole.
- Principal Component Analysis (PCA): PCA revealed that the 26 proteins were correlated and could be represented by four principal components, suggesting underlying biological relationships.
Limitations and Future Work
- Sample Size: The authors acknowledge that the study was conducted on a limited number of patients, which was intentional for validating the feasibility of the SRM approach. Future work should involve validation studies on larger cohorts encompassing various MS subtypes (RRMS, PPMS) and other neurological conditions.
- Protein Abundance: Some proteins previously reported in CSF were not detected, potentially due to low abundance or peptide instability. Improvements in sample preparation and instrument optimization could enhance the detection of these low-abundance proteins.
- Clinical Utility: While the identified proteins show differential expression, their clinical utility for diagnosis, prognosis, and therapeutic development needs further investigation in larger, prospective studies.
- Combinatorial Biomarkers: The study emphasizes the need for developing panels of biomarkers rather than relying on single markers, which will be a focus for future research.
- Broader Application: The developed SRM platform is presented as adaptable to studying a wide range of proteins, particularly those relevant to neurodegenerative diseases.
Summary updated